panel Archives - World Asthma Foundation

April 6, 2016

Metro-Boston Allergy & Asthma Educational Support Group to host panel discussion – Wicked Local

Metro-Boston Allergy & Asthma Educational Support Group to host panel discussion
Wicked Local
The Metro-Boston Allergy & Asthma Educational Support Group Parents will lead a panel discussion on adapting to life with food allergies and asthma, featuring parents of children of varying ages, at 7 p.m. April 13 at Newton-Wellesley Hospital, 2014 …
Allergy season gets an early start in MissoulaKITV Honolulu
Are Allergies The Result Of Better Hygiene?News/Talk 94.9 WSJM
Easing allergiesWXIX
WVTM13 –Daily Star Gazette
all 13 news articles »

View full post on asthma – Google News

December 11, 2015

FDA Panel Backs Reslizumab for Adults With Severe Asthma – Medscape

Medscape

FDA Panel Backs Reslizumab for Adults With Severe Asthma
Medscape
If approved by the FDA, it would be the third monoclonal antibody approved for asthma, after mepolizumab and omalizumab. Reslizumab binds to human interleukin-5 (IL-5). Several cytokines can affect eosinophils, but IL-5 is the main cytokine involved in …
FDA experts endorse Teva's asthma drug, but reject use in key patient groupFierceBiotech
FDA advisory panel recommends Teva asthma antibodyMedical Marketing and Media
FDA advisers recommend approval of Teva asthma drug in adultsFox News
Reuters –Business Wire (press release)
all 124 news articles »

View full post on asthma – Google News

June 18, 2015

FDA panel backs approval of GSK’s mepolizumab for severe asthma – ModernMedicine

FDA panel backs approval of GSK's mepolizumab for severe asthma
ModernMedicine
FDA's Pulmonary-Allergy Drugs Advisory Committee recently recommended approval of GlaxoSmithKline Plc's drug mepolizumab (Nucala) for severe asthma in patients aged 18 years and older. However, the panel voted 10 to 4 against approving the drug in …

and more »

View full post on asthma – Google News

June 12, 2015

FDA Panel Backs Mepolizumab for Severe Eosinophilic Asthma – Medscape

Medscape

FDA Panel Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape
A typical characteristic of mild asthma is airway inflammation due to eosinophils, and this inflammation is closely associated with the risk for severe asthma exacerbations. Several products are approved for long-term maintenance treatment of asthma …
FDA panel backs approval of GSK asthma drug in adultsReuters
Asthma Drug Targeting IL-5 Wins Partial Backing From FDA AdvisersMedPage Today
UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in …StreetInsider.com
Healio
all 17 news articles »

View full post on asthma – Google News

June 11, 2015

UPDATE 1-FDA panel backs approval of GSK asthma drug in adults – Reuters

MedPage Today

UPDATE 1-FDA panel backs approval of GSK asthma drug in adults
Reuters
If approved, the drug would be marketed under the trade name Nucala and be the first new biologic treatment for severe asthma in more than a decade. Asthma affects more than 22 million people in the United States. Severe asthma accounts for 5 to 10 …
UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in …StreetInsider.com
Asthma Drug Targeting IL-5 Wins Partial Backing From FDA AdvisersMedPage Today
FDA committee recommends approval of Nucala for adults with severe asthmaHealio
Reuters India
all 12 news articles »

View full post on asthma – Google News

June 11, 2015

FDA panel backs approval of GSK asthma drug in adults – Reuters

Reuters

FDA panel backs approval of GSK asthma drug in adults
Reuters
An advisory committee to the U.S. Food and Drug Administration recommended approval on Thursday of GlaxoSmithKline Plc's drug mepolizumab for severe asthma in patients aged 18 and older. The panel voted 10 to 4 against approving it in children aged …
UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in …StreetInsider.com
FDA committee recommends approval of Nucala for adults with severe asthmaHealio

all 8 news articles »

View full post on asthma – Google News

June 10, 2015

GSK asthma medication to go before FDA panel Thursday – Medical Marketing and Media

Medical Marketing and Media

GSK asthma medication to go before FDA panel Thursday
Medical Marketing and Media
GSK's struggle is tied to its blockbuster asthma drug Advair. The drugmaker not only had to lower the price of the branded medication before generic competition surfaced, but it has also failed to build a market for its successor line of Ellipta-based …

View full post on asthma – Google News

March 21, 2015

FDA Panel Recommends Asthma Treatment Approval for Adults Only – Pharmacy Times (registration)

Uncover California

FDA Panel Recommends Asthma Treatment Approval for Adults Only
Pharmacy Times (registration)
"We recognize the advisory committee's thoroughness in reviewing the data related to Breo Ellipta for asthma,” said Darrell Baker, senior vice president and head of GSK's Global Respiratory Franchise, in a press release. “We will continue to work …
GSK And Theravance: Implications Of The Advisory Panel DecisionSeeking Alpha (registration)
Breo Ellipta receives Mixed Views from FDA PanelUncover California

all 4 news articles »

View full post on asthma – Google News

March 20, 2015